TEL AVIV, Israel and MIAMI, Dec. 20, 2023 (GLOBE NEWSWIRE) — InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the issuance of U.S. Patent No. 11,844,893, titled, “Shunts with Blood Flow Indicators.” The patent covers key aspects of the […]
Neuro
Perfuze® Announces FDA Clearances for Novel Neurovascular Aspiration and Access Catheters for Stroke Treatment
ALWAY, Ireland–(BUSINESS WIRE)–Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, proudly announces FDA clearance for the Millipede 070 Aspiration Catheter and the 2nd generation of the Millipede 088 Access Catheter. “Perfuze aims to provide neurovascular interventionists with innovative thrombectomy solutions, to maximize their […]
Society of NeuroInterventional Surgery Congratulates President Mahesh Jayaraman, MD, FACR, on Appointment as Chair of Department of Diagnostic Imaging at Brown’s Warren Alpert Medical School
FAIRFAX, Va., Dec. 13, 2023 /PRNewswire/ — The Society of NeuroInterventional Surgery (SNIS) congratulates SNIS President Mahesh Jayaraman, MD, FACR, on his promotion to Chair of the Department of Diagnostic Imaging at The Warren Alpert Medical School of Brown University and Chief of Diagnostic Imaging at Lifespan, effective January 1, 2024. He will also be appointed the Charles and Elfriede Collis-Frances Weeden Gibson Professor of Diagnostic Imaging.
“I’m thrilled to congratulate Dr. Jayaraman on this well-deserved promotion. His groundbreaking research, strong leadership, and endless dedication to pursuing excellence makes him an invaluable asset to our field,” said SNIS Executive Director Marie Williams Denslow. “We are very grateful for his hard work, contributions, and commitment to his patients, and wish him success in his new roles.”
Dr. Jayaraman is recognized as a pioneering interventional neuroradiologist; his work has been published in more than 150 peer-reviewed journal articles, books and book chapters. He also serves as a Professor of Diagnostic Imaging, Neurology, and Neurosurgery at The Warren Alpert Medical School and the Director of the Neurovascular Center at Rhode Island Hospital. Under his direction, the center has gained international acclaim for providing cutting-edge care for patients with cerebrovascular disease.
As president of SNIS, Dr. Jayaraman leads SNIS in all its endeavors to enhance the field. Together SNIS members work to promote research, standard-setting, education and advocacy regarding diagnosing and treating diseases of the brain, spine, head and neck. With more than 1,000 members worldwide, the society is committed to providing the highest quality of patient care through these minimally invasive procedures.
Outside of his clinical work, Dr. Jayaraman has helped lead the SNIS effort to update stroke protocols across the nation through the association’s Get Ahead of Stroke® campaign. These policy changes help ensure that patients experiencing a severe stroke are transported directly to a Level 1 stroke center by EMS personnel. He championed this work in Rhode Island, resulting in statewide policy changes in 2016.
About the Society of NeuroInterventional Surgery
The Society of NeuroInterventional Surgery (SNIS) is a scientific and educational association dedicated to advancing the specialty of neurointerventional surgery through research, standard-setting, and education and advocacy to provide the highest quality of patient care in diagnosing and treating diseases of the brain, spine, head and neck. Visit www.snisonline.org and follow us on Twitter (@SNISinfo) and Facebook (@SNISOnline).
SOURCE The Society of NeuroInterventional Surgery (SNIS)
Q’Apel Medical Inc. Launches “Hippo” The New Generation Aspiration System for Stroke Thrombectomy
FREMONT, Calif., Dec. 12, 2023 /PRNewswire/ — Q’Apel Medical Inc. launches a new generation aspiration technology – the 072 Hippo Aspiration System, developed for patients suffering from a stroke due to a large vessel occlusion.
The recent FDA cleared stroke system, comprised of the 072 Hippo Aspiration Catheter and its Cheetah companion, represents a paradigm shift in emergent neurovascular intervention. The proprietary adaptive tip of the Hippo catheter redefines precision in clot engagement and removal, ensuring tailored performance for varying clot morphologies and sizes. This unique feature offers physicians real-time visibility and control during the critical phases of the procedure, providing insights previously unavailable. Visibility is crucial for the physician in confirming engagement with the culprit blockage, improving the odds for high first-pass success, and fewer passes, leading to better functional outcomes for stroke victims.
The adaptive tip of the Hippo catheter is complemented by the Cheetah, a flexible guiding companion designed to accelerate delivery of Hippo to the face of the clot. Together, Hippo and Cheetah create a synergistic system ensuring unparalleled speed, precision, and integration in thrombectomy procedures and is the ideal complement to Q’Apel’s market-leading Walrus Balloon Guide Catheter.
“Our initial experience with the Hippo Aspiration System really demonstrated outstanding system performance. In my opinion, the impact of a highly visible and adaptive catheter tip is superior to other aspiration systems. I can determine when my catheter is engaged with the clot, as I could see the tip conforming to the thrombus. Once the thrombus was removed, the petals returned to their original state, so I knew I had success”, said Raymond Turner, MD, Endovascular Neurosurgeon at PRISMA Health, Greenville, SC. “This adaptive and visible tip aids physicians in making informed decisions in real time, that leads to a successful thrombectomy outcomes for patients”.
“When every minute during a stroke kills 2 million neurons, speed is essential. The Hippo Cheetah combination allows for expediency with a high rate of first pass recanalization rates”, commented Elad Levy, MD, MBA, Professor and Chairman of Neurosurgery, Professor of Radiology, Department of Neurosurgery, Jacobs School of Medicine & Biomedical Sciences, Buffalo, NY.
“Hippo’s ability to adapt to various clot morphologies is impressive. Regardless of angulation I can confirm engagement of the catheter on the clot, as I can now visualize this – which has never been possible before in an aspiration catheter. Paired with the Cheetah delivery tool, this was a fast and easy system to use, and has the potential to be practice-changing and cost-saving”, said Omar Tanweer, MD Director of Cerebrovascular and Endovascular Neurosurgery, Baylor College of Medicine, Houston, TX.
“The anticipation of Hippo & Cheetah for Q’Apel has been enormous, and we are thrilled with the performance we have seen in clinic in our initial sites,” said King Nelson, Q’Apel Medical’s CEO. “It’s in Q’Apel’s DNA to bring to market highly differentiated products that truly provide a meaningful advantage and benefit to physicians and their patients. The Hippo Aspiration System also grants us the ability to offer physicians a complete stroke procedure. Hippo was designed to work with our market leading Balloon Guide Catheter, Walrus, and now we can marry the benefits of Walrus and the overwhelming evidence Balloon Guide Catheters offer with the game-changing technology of Hippo”.
About Q’Apel MedicalQ’Apel Medical designs highly innovative technologies for neurovascular interventions and unmet clinical needs. Q’Apel’s portfolio comprises the Walrus Balloon Catheter System, the Armadillo 7F and 6F Access System, and now the Hippo Aspiration System with its companion, Cheetah. Before Walrus came along, balloon-based variable stiffness catheters brought all manner of technological constraints. Not anymore. By blending flow control, trackability, support, and access into one revolutionary solution, Walrus offers truly unmatched functionality. The 7F and 6F Armadillo Access Systems are dual-mode catheters and part of the SelectFlex™ Family of Neurovascular Catheters. These devices feature two distinct operational modes, allowing physicians to easily switch modes at any point during a clinical case and reducing the need for multiple catheters in challenging procedures. The new addition of the Hippo Aspiration System provides visible feedback via its adaptive radiopaque tip for physicians and provides information for the physician that is vital during the procedure. Also, the 072 Hippo Aspiration System is compatible with the Walrus Balloon Guide catheter for a complete stroke solution.
Media Contact: Jodie Fam415 244 9885
[email protected] [email protected]www.qapelmedical.com
SOURCE Q’Apel Medical Inc.
RapidAI Announces a Series of Industry Firsts – Unique Rapid Edge Cloud Platform, Breakthrough AI Non-Contrast CT Suite, International Expansion in Japan
SAN MATEO, Calif.–(BUSINESS WIRE)–RapidAI, the global leader in developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, trauma, cardiac and vascular conditions, is proud to announce major milestones in advancing its industry-leading deep clinical AI, including: Launch of its unique AI-based healthcare platform, Rapid Edge Cloud*, a hybrid (cloud and on-premise) technology infrastructure built to be faster, more secure, and flexible,
Brainomix Targets US Expansion with the Launch of its Cutting-Edge Stroke AI Platform Following Series of FDA Clearances
Launched at the Society of Vascular and Interventional Neurology (SVIN) Conference in Miami, the Brainomix 360 platform is powered by best-in-class algorithms, delivering a unique technology for both specialist and non-specialist stroke centers that is poised to transform stroke care…
Route 92 Medical Announces Impressive Clinical Results for its Tenzing® Technology.
Multicenter clinical study showcases how Tenzing® technology is improving neurovascular intervention outcomes SAN MATEO, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — Route 92 Medical, a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced compelling results from a multicenter clinical study1 on the […]
RapidAI Receives FDA Clearance of AI Module for Detection of Hemispheric Subdural Hematomas
SAN MATEO, Calif.–(BUSINESS WIRE)–RapidAI, the global leader in developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, trauma, cardiac and vascular conditions, today announced it has received FDA clearance for Rapid SDH, its AI-powered module for the detection and notification of suspected hemispheric acute and chronic subdural hematoma. Together with Rapid ICH and Rapid Hyperdensity, the three modules comprise RapidAI’s unique and
Perfuze® Announces First Stroke Patient Enrolled in the MARRS Pivotal Clinical Trial for the Millipede System
GALWAY, Ireland–(BUSINESS WIRE)–Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, announced commencement of enrollment in its pivotal MARRS (Millipede AspiRation for Revascularization in Stroke) clinical study. MARRS is a multi-center trial to evaluate the performance of the Millipede System. The first patient was enrolled at Stony Brook University Hospital in Stony Brook, NY. “I am delighted to begin enrollment in the MARR
Texas County Memorial Hospital Goes Live with RapidAI to Enhance Neurovascular Decision Making and Rural Stroke Care
SAN MATEO, Calif. & HOUSTON, Mo.–(BUSINESS WIRE)–RapidAI, a global leader in developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac and vascular diseases, is pleased to announce Texas County Memorial Hospital’s (TCMH) implementation of RapidAI’s core stroke imaging and workflow products – including Rapid ICH, LVO, CTA and CTP – as part of its ongoing commitment to enhancing the quality of stroke care for patients in rural so



